<DOC>
	<DOCNO>NCT01174173</DOCNO>
	<brief_summary>The purpose study determine medication , ranolazine ( study drug ) , help improve blood flow heart , increase exercise capacity improve quality life ( QOL ) . For study , ask perform several test order determine heart function , exercise capacity , chest pain QOL improve 3 month treatment ranolazine . Ranolazine approve U.S. Food Drug Administration ( FDA ) treatment angina .</brief_summary>
	<brief_title>Ranolazine Pulmonary Hypertension</brief_title>
	<detailed_description>This study look enroll patient pulmonary hypertension ( PH ) . PH abnormally high blood pressure arteries lung . It make right side heart need work hard normal usually cause narrow small artery lung . This narrowing make hard right side heart circulate blood lung . Over time , right side heart may become enlarged symptom ( angina [ chest pain ] shortness breath , fatigue , edema ) begin appear . Ranolazine safe , well-tolerated , FDA-approved medication treatment chronic stable angina . Ranolazine may potentially improve blood flow right ventricle ( RV ) , thereby relieve angina simultaneously improve RV performance contractility . This latter effect may increase stroke volume cardiac output could translate benefit exercise capacity improve quality life . The purpose single center , non-randomized , prospective pilot study investigate effect 3 month treatment ranolazine pulmonary artery hemodynamics , exercise capacity quality life patient PAH symptom angina angina equivalent .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Inclusion criterion : 1 . World Health Organization ( WHO ) Group 1 PAH , define pulmonary hypertension mean pulmonary artery pressure &gt; 25 mmHg , pulmonary capillary wedge pressure &lt; 15 mmHg , pulmonary vascular resistance &gt; 3 Wood unit . 2 . Right ventricular dysfunction , define RV fractional area change &lt; 32 % RV tricuspid annular plane systolic excursion ( TAPSE ) &lt; 15 mm . 3 . Symptoms angina angina equivalent ( exertional dyspnea , exertional epigastric pain , exertional nausea ) . 4 . New York Heart Association functional class II III symptom . 5 . Stable dos pulmonary vasodilator ( prostacyclins , endothelin receptor antagonist , phosphodiesterase inhibitor ) , new therapy initiation dose escalation &gt; 50 % 4 week prior randomization . 6 . Age 1880 year . Exclusion criterion : 1 . Acute coronary syndrome coronary revascularization within prior 3 month . 2 . Patients unstable angina . 3 . Patients Class IV congestive heart failure . 4 . Planned revascularization , pacemaker defibrillator placement study period . 5 . Changes antianginal medical therapy likely occur study period . 6 . Corrected QT interval measurement &gt; 500 ms. 7 . Patients preexist QT prolongation ( include congenital long QT syndrome ) receive QT prolong drug ( include Class Ia—e.g. , quinidine , Class III—e.g. , dofetilide , sotalol , antiarrhythmic ; antipsychotic ( e.g. , thioridazine , ziprasidone ) , known history complex ventricular arrhythmia require antiarrhythmic medication ICD implantation . 8 . Patients known history hepatic dysfunction . 9 . Current use strong CYP3A inhibitor , include ketoconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir , saquinavir diltizaem . 10 . Patients pacemaker , cochlear implant , aneurysm clip , work metal . 11 . Patients metallic hardware , implant , prosthesis consult radiologist/cardiologist prior study . 12 . Patients severe end stage renal disease ( estimate GFR &lt; 30 mL/min/1.73 ) . 13 . Women pregnant lactate 14 . Any contraindication use right heart catheter include , limited : Pulmonic tricuspid valve stenosis Prosthetic pulmonic tricuspid valve Right atrial ventricular mass Previous pneumonectomy Risk severe arrhythmias , include leave bundle branch block ( LBBB ) 15 . Subjects unable perform cardiopulmonary exercise test exclude ( i.e . extensive musculoskeletal disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Angina</keyword>
	<keyword>Right Ventricular Ischemia</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>